MedNet Solutions
announced the official launch of its
iMedNet
CRO Partner Program. Designed specifically to help Clinical Research Organizations (CROs) improve research efficiency, expand their service offerings, decrease internal costs, and win more business, the program provides CROs with marketplace advantages.
At the core of the program is
iMedNet EDC
, MedNet's recently released cloud-based, software-as-a-service (SaaS) eClinical solution that allows non-technical clinical research personnel to quickly and easily set up and maintain their own EDC studies.
iMedNet EDC's
intuitive study configuration tools and form libraries allow studies to be set up in days, not weeks or months. Even entire studies can be replicated in a matter of seconds.
Key additional program features include:
Phase II Piranga Trial Shows Promise of Xalnesiran Combination for Hepatitis B Treatment
December 5th 2024Phase II Piranga trial found that the combination of xalnesiran and an immunomodulator effectively reduced hepatitis B surface antigen (HBsAg) levels, but highlighted challenges in response durability and efficacy in patients with high HBsAg levels.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Opdivo plus Yervoy Significantly Outperforms Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
December 2nd 2024Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.